Exelixis Inc (EXEL) 6.02 $EXEL
3 Biotech Stocks to Buy in November
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sun Nov 01, 12:20PM CST
Image Source TBIT via pixabay Well, that was fast. A month ago it seemed like biotech stocks couldn't do anything right. Shares of the iShares Nasdaq Biotechnology ETF , which holds a huge collection of biotech stocks, were pummeled over fears...
SGYP: 6.41 (-0.22), IRWD: 11.36 (+0.16), ALXN: 176.00 (+0.05), IBB: 325.46 (-3.09), EXEL: 6.02 (+0.14)
United Therapeutics Beats on Q3 Earnings, Revenues
Arpita Dutt - Zacks Investment Research - Wed Oct 28, 11:18AM CDT
United Therapeutics' (UTHR) third quarter results were better-than-expected with the company's products performing well.
MDT: 73.92 (+0.16), UTHR: 146.63 (+3.08), AMGN: 158.18 (-2.40), EXEL: 6.02 (+0.14)
Agenus Q3 Loss Wider than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Wed Oct 28, 10:50AM CDT
Agneus (AGEN) reported wider-than-expected loss.
AGEN: 4.56 (-0.07), AMGN: 158.18 (-2.40), EXEL: 6.02 (+0.14)
Exelixis Starts Cometriq Rolling NDA Filing for Kidney Cancer
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 1:36PM CDT
Exelixis (EXEL) has started the process of a rolling submission of a new drug application to the FDA for Cometriq for the treatment of advanced kidney cancer.
AZN: 31.89 (-0.35), AMGN: 158.18 (-2.40), EXEL: 6.02 (+0.14)
Covered Call Alerts For FireEye, Exelixis, eBay, Intuitive Surgical and SolarCity Released By InvestorsObserver
PR Newswire - Thu Oct 22, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FEYE, EXEL, EBAY, ISRG and SCTY.
ISRG: 496.60 (-3.68), FEYE: 26.15 (-0.75), EBAY: 27.90 (-0.27), SCTY: 29.65 (-8.42), EXEL: 6.02 (+0.14)
Exelixis Initiates Rolling Submission of U.S. New Drug Application for Cabozantinib for the Treatment of Advanced Kidney Cancer
Business Wire - Thu Oct 22, 7:00AM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced the company has initiated submission of its rolling New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for cabozantinib for the treatment of advanced renal cell carcinoma (RCC) patients who have received one prior therapy. Cabozantinib was granted Breakthrough Therapy Designation by the FDA in August 2015. Exelixis agreed with FDA that the submission would be a rolling NDA and the company has filed the first component of the application for potential approval of cabozantinib in the United States. The rolling NDA allows completed portions of an NDA to be submitted and reviewed by the FDA on an ongoing basis. Exelixis plans to complete the NDA submission before the end of 2015.
EXEL: 6.02 (+0.14)
Exelixis to Release Third Quarter 2015 Financial Results on Tuesday, November 10, 2015
Business Wire - Tue Oct 20, 3:42PM CDT
Exelixis, Inc. (NASDAQ: EXEL) announced today that its third quarter 2015 financial results will be released on Tuesday, November 10, 2015 after the markets close. At 5:00 p.m. EST / 2:00 p.m. PST, Exelixis management will host a conference call to discuss the results and provide a general business update. The conference call will be accessible via the Internet from the company's website.
EXEL: 6.02 (+0.14)
Critical Alerts For Linn Energy, Autodesk, Palo Alto Networks, Exelixis and MannKind Released By InvestorsObserver
PR Newswire - Mon Oct 12, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for LINE, ADSK, PANW, EXEL and MNKD.
LINE: 2.54 (+0.10), MNKD: 3.31 (-0.15), PANW: 161.00 (+3.10), ADSK: 55.19 (+0.13), EXEL: 6.02 (+0.14)
How Much Could Exelixis Really Be Worth?
Sean Williams, The Motley Fool - Motley Fool - Fri Oct 09, 1:03PM CDT
Image source: Federal Reserve Bank of New York. Shareholders of biotechnology company Exelixis have had an exceptional year in spite of witnessing many biotech stocks giving back all of their gains for the year. Since Dec. 31, 2014, and through...
EXEL: 6.02 (+0.14)
Roche (RHHBY) Reports Positive Data on Skin Cancer Drugs
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 3:55PM CDT
Roche (RHHBY) announced positive data from a phase III study, coBRIM, on Zelboraf in combination with Cotellic (cobimetinib).
ABT: 44.80 (-0.44), NVO: 53.18 (+0.12), EXEL: 6.02 (+0.14)
Exelixis Announces Positive Overall Survival Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma
Business Wire - Tue Oct 06, 12:00AM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced positive overall survival (OS) results from coBRIM, the phase 3 pivotal trial evaluating cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma carrying a BRAF V600 mutation. Exelixis' collaborator Genentech, a member of the Roche Group, informed the company that coBRIM met its secondary endpoint of demonstrating a statistically significant and clinically meaningful increase in overall survival for patients receiving the combination of cobimetinib and vemurafenib, as compared to vemurafenib monotherapy. Ongoing study monitoring did not identify any new safety signals. Long-term safety data are expected later this year. These data will be the subject of a presentation at an upcoming medical meeting.
EXEL: 6.02 (+0.14)
Kidney Cancer Drug Boxing Match
Brian Orelli, The Motley Fool - Motley Fool - Sun Oct 04, 12:20PM CDT
Let the kidney cancer battle begin. In this corner, weighing in at a market cap around $100 billion, is Bristol-Myers Squibb and its immunotherapy drug Opdivo. And in this corner, weighing in at a mere $1.3 billion, is Exelixis and its...
BMY: 65.95 (-1.36), NVS: 90.43 (-0.53), EXEL: 6.02 (+0.14)
10 Best Nasdaq Biotech Stocks in the Third Quarter
at The Street - Wed Sep 30, 3:36PM CDT
Here are the 10 stocks in the biotech sector which had the best third-quarter.
CARA: 14.17 (-0.96), MYGN: 40.37 (-0.78), ZSPH: 65.01 (-0.97), MDCO: 34.24 (+0.29), LXRX: 9.51 (-0.26), INCY: 117.53 (+0.50), SCMP: 19.36 (+0.25), ANAC: 112.41 (+7.08), CNCE: 22.71 (-0.36), EXEL: 6.02 (+0.14)
Technical Review on Healthcare and Financial Sectors -- Two Harbors Investments, Hudson City Bancorp, Novavax, Opko Health and Exelixis
PR Newswire - Wed Sep 30, 9:31AM CDT
ACI Association has initiated research coverage on the following equities: Two Harbors Investments Corp (NYSE: TWO), Hudson City Bancorp, Inc. (NASDAQ: HCBK), Novavax, Inc. (NASDAQ: NVAX), Opko Health Inc (NYSE: OPK), Exelixis, Inc. (NASDAQ: EXEL). On Tuesday, September 29, 2015, Nasdaq ended at 4517.32, down 0.59%, Dow Jones advanced 0.30%, to finish the day at 16049.13, and the S&P closed at 1884.09, up 0.12%. Register for your complimentary reports at the links given below.
OPK: 9.45 (+0.06), NVAX: 6.75 (-0.13), TWO: 8.46 (-0.13), HCBK: 10.12 (-0.07), EXEL: 6.02 (+0.14)
4 Stocks Under $10 Making Big Moves Higher
at The Street - Tue Sep 29, 1:46PM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
PBMD: 1.22 (+0.01), MCUR: 1.42 (+0.07), IPI: 3.86 (-0.22), EXEL: 6.02 (+0.14)
Don't Panic! These 3 Beaten Down Biotech Stocks Are Now Great Buys
George Budwell, The Motley Fool - Motley Fool - Tue Sep 29, 12:03PM CDT
The moody market has taken its wrath out on biotech stocks far and wide in September. In fact, biotechs are some of the worst-performing stocks for the month: As the cover to "The Hitchhiker's Guide to the Galaxy" emphatically reminds us,...
AGEN: 4.56 (-0.07), TRVN: 9.62 (-0.27), EXEL: 6.02 (+0.14)
Exelixis Announces Positive Results from METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Presented at European Cancer Congress 2015
Business Wire - Fri Sep 25, 5:09PM CDT
--- Cabozantinib showed a strong trend towards improving overall survival as compared to everolimus at an interim analysis -
EXEL: 6.02 (+0.14)
Bristol, Exelixis Drugs Demonstrate Treatment Benefit in Kidney Cancer
at The Street - Fri Sep 25, 5:02PM CDT
Bristol's Opdivo is likely to be used ahead of Exelixis' Cometriq to treat advanced kidney cancer patients, doctor says.
PFE: 33.82 (-0.95), MRK: 54.66 (-0.21), BMY: 65.95 (-1.36), EXEL: 6.02 (+0.14), NVS: 90.43 (-0.53)
European CHMP Adopts Positive Opinion for Cobimetinib in Combination with Vemurafenib for the Treatment of Advanced Melanoma
Business Wire - Fri Sep 25, 6:41AM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced that the European Medicines Agency's Committee for Medical Products for Human Use (CHMP) has adopted a positive opinion of the Marketing Authorization Application for cobimetinib, a selective MEK inhibitor discovered by Exelixis, in combination with vemurafenib for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. The CHMP's positive opinion will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union. The European Commission is expected to release its final decision regarding the approval of the combination of cobimetinib and vemurafenib by the end of 2015.
EXEL: 6.02 (+0.14)
Covered Call Alerts For Exelixis, Heron Therapeutics, BP, Micron and Qihoo 360 Technology Released By InvestorsObserver
PR Newswire - Thu Sep 24, 8:31AM CDT
InvestorsObserver has issued critical PriceWatch Alerts for EXEL, HRTX, BP, QIHU and ARIA.
QIHU: 57.09 (unch), HRTX: 27.42 (-0.05), BP: 35.70 (-0.01), ARIA: 6.84 (unch), EXEL: 6.02 (+0.14)
3 Biotech Stocks to Buy in November
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sun Nov 01, 12:20PM CST
Image Source TBIT via pixabay Well, that was fast. A month ago it seemed like biotech stocks couldn't do anything right. Shares of the iShares Nasdaq Biotechnology ETF , which holds a huge collection of biotech stocks, were pummeled over fears...
SGYP: 6.41 (-0.22), IRWD: 11.36 (+0.16), ALXN: 176.00 (+0.05), IBB: 325.46 (-3.09), EXEL: 6.02 (+0.14)
United Therapeutics Beats on Q3 Earnings, Revenues
Arpita Dutt - Zacks Investment Research - Wed Oct 28, 11:18AM CDT
United Therapeutics' (UTHR) third quarter results were better-than-expected with the company's products performing well.
MDT: 73.92 (+0.16), UTHR: 146.63 (+3.08), AMGN: 158.18 (-2.40), EXEL: 6.02 (+0.14)
Agenus Q3 Loss Wider than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Wed Oct 28, 10:50AM CDT
Agneus (AGEN) reported wider-than-expected loss.
AGEN: 4.56 (-0.07), AMGN: 158.18 (-2.40), EXEL: 6.02 (+0.14)
Exelixis Starts Cometriq Rolling NDA Filing for Kidney Cancer
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 1:36PM CDT
Exelixis (EXEL) has started the process of a rolling submission of a new drug application to the FDA for Cometriq for the treatment of advanced kidney cancer.
AZN: 31.89 (-0.35), AMGN: 158.18 (-2.40), EXEL: 6.02 (+0.14)
Covered Call Alerts For FireEye, Exelixis, eBay, Intuitive Surgical and SolarCity Released By InvestorsObserver
PR Newswire - Thu Oct 22, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FEYE, EXEL, EBAY, ISRG and SCTY.
ISRG: 496.60 (-3.68), FEYE: 26.15 (-0.75), EBAY: 27.90 (-0.27), SCTY: 29.65 (-8.42), EXEL: 6.02 (+0.14)
Exelixis Initiates Rolling Submission of U.S. New Drug Application for Cabozantinib for the Treatment of Advanced Kidney Cancer
Business Wire - Thu Oct 22, 7:00AM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced the company has initiated submission of its rolling New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for cabozantinib for the treatment of advanced renal cell carcinoma (RCC) patients who have received one prior therapy. Cabozantinib was granted Breakthrough Therapy Designation by the FDA in August 2015. Exelixis agreed with FDA that the submission would be a rolling NDA and the company has filed the first component of the application for potential approval of cabozantinib in the United States. The rolling NDA allows completed portions of an NDA to be submitted and reviewed by the FDA on an ongoing basis. Exelixis plans to complete the NDA submission before the end of 2015.
EXEL: 6.02 (+0.14)
Exelixis to Release Third Quarter 2015 Financial Results on Tuesday, November 10, 2015
Business Wire - Tue Oct 20, 3:42PM CDT
Exelixis, Inc. (NASDAQ: EXEL) announced today that its third quarter 2015 financial results will be released on Tuesday, November 10, 2015 after the markets close. At 5:00 p.m. EST / 2:00 p.m. PST, Exelixis management will host a conference call to discuss the results and provide a general business update. The conference call will be accessible via the Internet from the company's website.
EXEL: 6.02 (+0.14)
Critical Alerts For Linn Energy, Autodesk, Palo Alto Networks, Exelixis and MannKind Released By InvestorsObserver
PR Newswire - Mon Oct 12, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for LINE, ADSK, PANW, EXEL and MNKD.
LINE: 2.54 (+0.10), MNKD: 3.31 (-0.15), PANW: 161.00 (+3.10), ADSK: 55.19 (+0.13), EXEL: 6.02 (+0.14)
How Much Could Exelixis Really Be Worth?
Sean Williams, The Motley Fool - Motley Fool - Fri Oct 09, 1:03PM CDT
Image source: Federal Reserve Bank of New York. Shareholders of biotechnology company Exelixis have had an exceptional year in spite of witnessing many biotech stocks giving back all of their gains for the year. Since Dec. 31, 2014, and through...
EXEL: 6.02 (+0.14)
Roche (RHHBY) Reports Positive Data on Skin Cancer Drugs
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 3:55PM CDT
Roche (RHHBY) announced positive data from a phase III study, coBRIM, on Zelboraf in combination with Cotellic (cobimetinib).
ABT: 44.80 (-0.44), NVO: 53.18 (+0.12), EXEL: 6.02 (+0.14)
Exelixis Announces Positive Overall Survival Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma
Business Wire - Tue Oct 06, 12:00AM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced positive overall survival (OS) results from coBRIM, the phase 3 pivotal trial evaluating cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma carrying a BRAF V600 mutation. Exelixis' collaborator Genentech, a member of the Roche Group, informed the company that coBRIM met its secondary endpoint of demonstrating a statistically significant and clinically meaningful increase in overall survival for patients receiving the combination of cobimetinib and vemurafenib, as compared to vemurafenib monotherapy. Ongoing study monitoring did not identify any new safety signals. Long-term safety data are expected later this year. These data will be the subject of a presentation at an upcoming medical meeting.
EXEL: 6.02 (+0.14)
Kidney Cancer Drug Boxing Match
Brian Orelli, The Motley Fool - Motley Fool - Sun Oct 04, 12:20PM CDT
Let the kidney cancer battle begin. In this corner, weighing in at a market cap around $100 billion, is Bristol-Myers Squibb and its immunotherapy drug Opdivo. And in this corner, weighing in at a mere $1.3 billion, is Exelixis and its...
BMY: 65.95 (-1.36), NVS: 90.43 (-0.53), EXEL: 6.02 (+0.14)
10 Best Nasdaq Biotech Stocks in the Third Quarter
at The Street - Wed Sep 30, 3:36PM CDT
Here are the 10 stocks in the biotech sector which had the best third-quarter.
CARA: 14.17 (-0.96), MYGN: 40.37 (-0.78), ZSPH: 65.01 (-0.97), MDCO: 34.24 (+0.29), LXRX: 9.51 (-0.26), INCY: 117.53 (+0.50), SCMP: 19.36 (+0.25), ANAC: 112.41 (+7.08), CNCE: 22.71 (-0.36), EXEL: 6.02 (+0.14)
Technical Review on Healthcare and Financial Sectors -- Two Harbors Investments, Hudson City Bancorp, Novavax, Opko Health and Exelixis
PR Newswire - Wed Sep 30, 9:31AM CDT
ACI Association has initiated research coverage on the following equities: Two Harbors Investments Corp (NYSE: TWO), Hudson City Bancorp, Inc. (NASDAQ: HCBK), Novavax, Inc. (NASDAQ: NVAX), Opko Health Inc (NYSE: OPK), Exelixis, Inc. (NASDAQ: EXEL). On Tuesday, September 29, 2015, Nasdaq ended at 4517.32, down 0.59%, Dow Jones advanced 0.30%, to finish the day at 16049.13, and the S&P closed at 1884.09, up 0.12%. Register for your complimentary reports at the links given below.
OPK: 9.45 (+0.06), NVAX: 6.75 (-0.13), TWO: 8.46 (-0.13), HCBK: 10.12 (-0.07), EXEL: 6.02 (+0.14)
4 Stocks Under $10 Making Big Moves Higher
at The Street - Tue Sep 29, 1:46PM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
PBMD: 1.22 (+0.01), MCUR: 1.42 (+0.07), IPI: 3.86 (-0.22), EXEL: 6.02 (+0.14)
Don't Panic! These 3 Beaten Down Biotech Stocks Are Now Great Buys
George Budwell, The Motley Fool - Motley Fool - Tue Sep 29, 12:03PM CDT
The moody market has taken its wrath out on biotech stocks far and wide in September. In fact, biotechs are some of the worst-performing stocks for the month: As the cover to "The Hitchhiker's Guide to the Galaxy" emphatically reminds us,...
AGEN: 4.56 (-0.07), TRVN: 9.62 (-0.27), EXEL: 6.02 (+0.14)
Exelixis Announces Positive Results from METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Presented at European Cancer Congress 2015
Business Wire - Fri Sep 25, 5:09PM CDT
--- Cabozantinib showed a strong trend towards improving overall survival as compared to everolimus at an interim analysis -
EXEL: 6.02 (+0.14)
Bristol, Exelixis Drugs Demonstrate Treatment Benefit in Kidney Cancer
at The Street - Fri Sep 25, 5:02PM CDT
Bristol's Opdivo is likely to be used ahead of Exelixis' Cometriq to treat advanced kidney cancer patients, doctor says.
PFE: 33.82 (-0.95), MRK: 54.66 (-0.21), BMY: 65.95 (-1.36), EXEL: 6.02 (+0.14), NVS: 90.43 (-0.53)
European CHMP Adopts Positive Opinion for Cobimetinib in Combination with Vemurafenib for the Treatment of Advanced Melanoma
Business Wire - Fri Sep 25, 6:41AM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced that the European Medicines Agency's Committee for Medical Products for Human Use (CHMP) has adopted a positive opinion of the Marketing Authorization Application for cobimetinib, a selective MEK inhibitor discovered by Exelixis, in combination with vemurafenib for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. The CHMP's positive opinion will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union. The European Commission is expected to release its final decision regarding the approval of the combination of cobimetinib and vemurafenib by the end of 2015.
EXEL: 6.02 (+0.14)
Covered Call Alerts For Exelixis, Heron Therapeutics, BP, Micron and Qihoo 360 Technology Released By InvestorsObserver
PR Newswire - Thu Sep 24, 8:31AM CDT
InvestorsObserver has issued critical PriceWatch Alerts for EXEL, HRTX, BP, QIHU and ARIA.
QIHU: 57.09 (unch), HRTX: 27.42 (-0.05), BP: 35.70 (-0.01), ARIA: 6.84 (unch), EXEL: 6.02 (+0.14)
